NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/03/2026 14:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization365.91 mln
Float36.62 mln
Earnings Date08/12/2026
EPS
0.95
Decent
P / E
6.64
Undervalued
Piotroski F-Score
6
/ 9
Solid
Relative Strength
25
/ 100
Underperforming
Debt / Equity
0.16
Very low leverage
ROE
48.60
Very strong
Business Description
Abeona Therapeutics is a US-based biopharmaceutical company focused on developing gene and cell therapies for serious, life-threatening conditions. Its leading product, ZEVASKYN, is designed to treat recessive dystrophic epidermolysis bullosa, a severe skin disorder, while its pipeline includes additional therapies targeting rare eye diseases such as X-linked retinoschisis, Stargardt disease, and autosomal dominant optic atrophy. Founded in 1974 and headquartered in Cleveland, Ohio, the company also advances a broader gene therapy platform aimed at addressing other difficult-to-treat conditions.
